You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AZ’s Fasenra hits the mark in phase IIIb asthma trial

AstraZeneca’s monoclonal antibody (mAb) significantly eliminated oral corticosteroid (OCS) use in OCS-dependent asthma patients with a broad range of blood eosinophils counts.